![Mononegavirales / Human respiratory syncytial virus / Palivizumab / Biology / Health / MedImmune / Placebo / AstraZeneca / Medicine / Viral diseases Mononegavirales / Human respiratory syncytial virus / Palivizumab / Biology / Health / MedImmune / Placebo / AstraZeneca / Medicine / Viral diseases](https://www.pdfsearch.io/img/5b29e18508a94aa4d906cb6a3c28452f.jpg) Date: 2014-04-30 14:26:38Mononegavirales Human respiratory syncytial virus Palivizumab Biology Health MedImmune Placebo AstraZeneca Medicine Viral diseases | | Synagis® has been shown to reduce the rate of RSV-related hospitalizations in premature infants (≤35 weeks GA) by more than half 1 Significant reduction in RSV-related hospitalization rates with Synagis vs. placebo1-3Add to Reading ListSource URL: www.rsvfacts.comDownload Document from Source Website File Size: 83,75 KBShare Document on Facebook
|